Swiss attorney general isn’t prosecuting Novartis for bribery; Madrigal to raise $200M in stock sale

→ The Swiss attorney general’s office will not be prosecuting Novartis for the $1.2 million in payments the company made to President Trump’s lawyer. The Swiss pharma giant was lambasted last month when the suspicious transactions came to light. Novartis says it was engaging Essential Consultants, attorney Michael Cohen’s company, to provide “health care policy” advice and gain “inroads” to the new administration. Novartis has since called the pact a mistake.

On Wednesday, the Swiss attorney general’s office said it had received a criminal complaint “alleging the bribery of foreign public officials by Novartis and by unidentified Novartis employees.” But after looking into it, the OAG says “there was insufficient suspicion to justify opening criminal proceedings.”

→ Taking advantage of the big spike in its stock price after posting encouraging results on their new NASH drug, Madrigal Pharmaceuticals $MDGL says it will raise $200 million through a stock sale.

→ South San Francisco-based Senti Biosciences has recruited Curt Herberts as chief financial officer and chief business officer. Most recently, Herberts served as CBO at Sangamo Therapeutics.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 48,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->